Direct answer:On 22 October 2026, the FDA issued a final guide on the mandatory recall of cosmetics, explaining the existing statutory powers, applicable conditions and procedures that MoCRA has added. Not every label or quality problem automatically triggers a mandatory recall, nor does this guide create a new recall system. ALREG recommends that brand parties and other duty-bearers reconcile the division of responsibilities, batch flows and incident communication mechanisms.

File information:Final industry guidelines; (a) Interpretation of existing legal competence; Institutions: FDA; Original proclamation: 2026-10-22; No new uniform implementation date is available; The station was first published and recently checked: 2026-11-10.See Official Original。

What is this file, at what stage?

File As Questions and Answers Regarding Mandatory Cosmetics Recalls: Guidance for IndustryFDA Final Industry Guide, Case File FDA-2025-D-2246, October 2026. The thematic bulletin of the FDA is dated 2026-10-22.

Guidance interpretation FD&C Act 611, which was increased by MoCRA. The FDA indicated that the draft issued at this time, 2025-12-18, had been finalized without substantive changes. The guide itself is non-binding; The legal obligations cited therein derive from the corresponding laws and regulations and cannot be summarized in new legislation.

Which enterprises and products need attention?

ProductsRelated rolesBusiness of concern
Products that meet the definition of American cosmeticsApplied manufacturers, packaging agents or distributors listed on labelsConfirm MoCRA responsible person, coordinate events and recall
Cosmetics for the United States marketSubstitute factories, brand parties, importers and distributorsEstablishment of product batch, flow and contact information handovers
Products with pharmaceutical products or instruments to control identityGroup on Classification and Regulatory ResponsibilityOther applicable rights under Article 613 and specific products, not directly applied under Article 611

Here, responsible person is the applicable manufacturer, packaging or distributor whose name appears on the label, as defined by the relevant legislation. The establishment U.S. agent, importer, brander and factory should be required to establish liability according to the true label and business relationship, and legal liability cannot be presumed to have been transferred solely on the basis of the signing of the agency contract.

Where is the change from what was previously requested?

MattersPrior statusContents of this documentOfficial sources
Mandatory recall permissionsMoCRA has granted statutory authority to FDADescription of when and how article 611 is applied is not newBackground to the guide and questions and answers 4-8
Document phaseDraft published in December 2025Finalization, FDA bulletin says no substantive changesFDA 2026-10-22
Business responseVoluntary recall is still a common practice.Interpretation of suspension of distribution, opportunities for voluntary disposal and order proceduresQuestions and answers on the guide 5-8

The FDA uses Article 611 authority to determine two conditions: there is a reasonable possibility that cosmetics are mixed or mislabelled and that there is a reasonable likelihood that use or contact of the product will cause serious adverse health consequences or death. Minor scheduling problems or any complaints cannot be directly equated with meeting this threshold.

Key dates and transitional arrangements

  • 2025-12-18: Date of publication of drafts listed in the FDA Bulletin.
  • 2026-10-22: FDA issues a thematic bulletin on the final guide.
  • 2026-11-10: Date of the station’s first release and data reconciliation.

The guide does not provide a uniform recall date or additional waiting period for all new enterprises. When an FDA notification or order is actually received, it shall be dealt with in accordance with the relevant procedures and documentation; The opportunity for informal hearings described in the guide does not mean that the applicable stop-distribution order can be ignored while waiting.

How can Chinese companies prepare?

The following is a proposal for an ALREG, which cannot be considered as a new set of fixed tables for all enterprises by the FDA:

  1. Check product classifications, United States labels and listed subjects to identify contact, decision-making and authorization arrangements between responsible persons.
  2. Establish a correspondence between product, formulation, production and packaging batches and United States customers or distribution flows, and identify how to access them in a timely manner when needed.
  3. Bringing together complaints, adverse events, inspection results and vendor quality information to the appropriate personnel to assess risks and other applicable reporting obligations on the basis of facts.
  4. Agreement to discontinue internal processes for distribution, voluntary recall, notification of clients and collaboration of channels, and verification of the division of labour for the transfer of information in contracts.
  5. Preparation of retrospective communication, recovery, disposal and progress records; Once a specific FDA document is received, it will be implemented according to its scope, timing and requirements.
  6. Recall plans and contact points are checked for availability on a regular basis to translate the problems identified by the exercise or review into improvements.

Exceptions, pending confirmations and common misreading

  • The threshold for compulsory recall is not “automatic recall for any non-compliance”; It still needs to be judged in terms of legal conditions and product facts.
  • FDA usually gives the responsible person the opportunity to voluntarily stop distribution and recall; If not dealt with as required, the procedure for suspension of distribution orders, hearings and follow-up decisions may be entered in accordance with the law.
  • Voluntary recall remains important, and the absence of a mandatory order should not lead to the neglect of identified security or compliance issues.
  • Products with pharmaceutical or instrument identity should not be analysed solely on the basis of normal cosmetics article 611 process analysis, with instructional questions and answers2 requiring verification of other applicable rights.
  • The registration of MoCRA facilities, the product listing or commissioning of U.S. agents are not grounds for exemption from recall and other applicable obligations.

Official information and reconciliation records

  1. Thematic bulletin on the publication of the final guide (2026-10-22), quote the final state, the history of the draft and the absence of substantive changes.
  2. FDA Final Guide Page; Case file FDA-2025-D-2246.
  3. FDA Final Guide PDF (October 2026), with emphasis on background, question and answer 1-8 (PDF pp. 3-6), including scope, responsible persons, thresholds and procedures.

Check date: 2026-11-10. Review triggers: revision or withdrawal of the guidelines, changes in legislation, changes in product classification or label liability, and specific FDA notifications or orders.

Next

Enterprises can first collate United States labels, inter-party relationships, batch retroactive and incident processing processes and reconcile responsibilities and information gaps. AccessibleMoCRA Guide to Registration and ListingandCosmetics FDA Compliance Service Scope。 Whether specific tasks such as recall enforcement, case-control response, etc. are available requires confirmation of the specific scope and division of labour.

View cosmetics FDA compliance service range

Submission of products and operations, verification of scope of application *

For the first time, the station publishes, updates and collates information: 2026-11-10. Author: Mr. Otsun; Audit: Mr. Toto. This paper distinguishes between the official rules and the Centre’s proposals, and individual cases need to be checked against specific facts.